83741-35-9

Usage

Uses

Used in Pharmaceutical Industry:
1H-Benzimidazole,4-bromo-(9CI) is used as a key intermediate in the synthesis of various drug candidates and bioactive molecules. Its unique structure and reactivity make it a versatile component in the development of new therapeutic agents.
Used in Cancer Treatment:
1H-Benzimidazole,4-bromo-(9CI) is used in the preparation of antibody drug conjugates (ADCs) with nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. These ADCs are designed for the targeted treatment of cancer, as they can specifically deliver the NAMPT inhibitors to cancer cells, thereby inhibiting their growth and proliferation.
The use of 1H-Benzimidazole,4-bromo-(9CI) in the development of ADCs with NAMPT inhibitors offers a promising approach for the treatment of various types of cancer. By leveraging the selective targeting capabilities of antibodies and the potent inhibitory effects of NAMPT inhibitors, these conjugates can potentially improve the efficacy and safety of cancer therapies, while minimizing side effects and drug resistance issues associated with conventional chemotherapy.

InChI:InChI=1/C7H5BrN2/c8-5-2-1-3-6-7(5)10-4-9-6/h1-4H,(H,9,10)

Upstream product

• 64-18-6 formic acid 
• 1575-36-6 3-bromobenzene-1,2-diamine 
• 7138-15-0 3-bromo-2-nitrophenylamine 
• 122-51-0 orthoformic acid triethyl ester 
• 59255-95-7 2-bromo-6-nitroaniline 
• 16712-16-6 ammonium formate 
• 19613-76-4 1-bromo-2,3-dinitro-benzene 

Downstream Products

• 247083-08-5 4-bromo-1-trityl-1H-benzo[d]imidazole 
• 1299292-28-6 7-bromo-1-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)benzimidazole 
• 1299292-25-3 4-bromo-1-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)benzimidazole 
• 247083-12-1 4-(piperazin-1-yl)-1-trityl-1H-benzo[d]imidazole 

Relevant academic research and scientific papers

SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

Microwave use of amidine compounds in the aqueous phase benzoate synthesis of benzimidazole compounds method

The invention discloses a microwave the use of amidine compounds in the aqueous phase benzoate synthesis of benzimidazole compounds, in the aqueous phase under microwave conditions adding benzoic amidine compound under alkaline condition [...] into benzimidazole reaction, invention an environment-friendly, the operation is simple, cheap and safe, efficient process for preparing benzimidazole method. Compared with the prior art, this method not only can be applied to a large number of functional groups, the productive rate is high, few by-products, and the operation is simple, safe, low cost, environmental protection; .

STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES

The application relates to compounds of Formula (I'): which modulate the activity of a kinase (e.g., STK4), a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease or disorder associated with the modulation of a kinase, such as STK4.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described

SERINE/THREONINE PAK1 INHIBITORS

Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.

BENZOTHIOPHENE SULFONAMIDES AND OTHER COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN

The present invention relates to benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

ARYLSULFONYLNAPHTHALENE DERIVATIVES AS 5HT2A ANTAGONISTS

Compounds of formula (I) are potent and selective 5-HT2A antagonists, useful in treatment of a variety of adverse conditions of the CNS.

ARYLSULFONYL BENZYL ETHERS AS 5-HT2A ANTAGONISTS

Compounds of formula (I) are potent and selective antagonists of the 5-HT2A receptor, and hence are useful in treatment of various CNS disorders.

DIARYLSULFONES AS 5-HT2A ANTAGONISTS

Compounds of formula (I) are potent and selective antagonists of the human 5-HT2A receptor, and hence useful in treatment of a variety of adverse conditions of the CNS.